A long term observational ocular safety study in adults who have received study medication
(either active drug or placebo) in a phase II or III clinical study evaluating eltrombopag.
The study will follow subjects for 2.5 years following their last ocular assessment on their
prior treatment study (regardless of the therapeutic indication) and will describe long-term
ocular safety with respect to changes in the lenses over time from all subjects.